UBS Maintains Neutral on Pfizer, Raises Price Target to $27

Benzinga Newsdesk www.benzinga.com Positive 62.1%

Neg 0% Neu 0% Pos 62.1%

UBS analyst Michael Yee maintains Pfizer (NYSE:PFE) with a Neutral and raises the price target from $25 to $27.

Comments

No comments yet. Be the first!